华东医药：2021年年度报告（英文版）.PDF

1、The 2021 Annual Report of Huadong Medicine Co.,Ltd.1 Huadong Medicine Co.,Ltd.2021 Annual Report April 2022 The 2021 Annual Report of Huadong Medicine Co.,Ltd.2 To the shareholders Dear shareholders,Time flies.Nearly three years have passed since I served as the Chairman of the Board of Huadong Medi

2、cine Co.,Ltd,during which I have witnessed the historic changes in the pharmaceutical industry of China.Like most domestic pharmaceutical companies,we are confronted with unprecedented difficulties and dramatic challenges in this ever-changing era.The continued implementation of VBP program and the

3、negotiation on medical insurance put an end to the benefits of generic medicines,moreover，the resurgence of COVID-19 and the instable external environment placed more uncertainties within local pharmaceutical industry.Bearing in mind the major mission of generating business growth,the management tea

4、m of the Company struggled onward amid the pains that come with changes,reform and transformation.It cannot be denied that the Companys financial statements over the past three years was not as outstanding as that in the previous time.However,all employees in the Company weathered the test of time a

5、nd flagging market,achieving innovation-driven results that transcend financial statements by focusing on the transformation and innovation.From 2019 to 2021,while reconsidered its positioning and value,the Company recruited more talents,developed product pipelines faster,made greater progress in R&

6、D capability building and achieved more improvements in comprehensive strength than ever before,introducing tremendous changes in and outside the Company.In the past three years,we implemented in nearly 20 BD transactions with leading international pharmaceutical companies to create a global collabo